Articles related to PTSD

Growing evidence suggests that exposure to natural environments may improve mood, attention, and selected cognitive functions, although the current literature remains insufficient to establish nature-based interventions as validated treatments for psychiatric disorders.

Magnetoencephalography-based analysis of 263 patients with major depressive disorder identified five distinct brain connectivity profiles, each associated with differing symptom patterns, supporting the view that depression may encompass biologically heterogeneous subgroups rather than a single neurobiological condition.

Childhood trauma was associated with altered hippocampal reward-pathway connectivity and greater adult anhedonia in a large neuroimaging cohort. The findings identify a potential neurobiological link but did not establish causality.

Short-term benzodiazepine use after mass trauma was not associated with increased 12-month PTSD risk in a large retrospective cohort. Persistent use showed a different pattern, and the observational findings did not establish causality.

An EEG-guided neuromodulation system received FDA clearance for PTSD treatment based on a randomized controlled trial. The platform uses individualized brain activity data to guide therapy, though detailed efficacy results have not been disclosed.

FDA priority review vouchers granted to three psychedelic developers and a recent executive order may accelerate regulatory timelines for psilocybin and related compounds, with clinical availability potentially within 12 months pending positive Phase 3 data.